X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs GSK PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB GSK PHARMA DR. REDDYS LAB/
GSK PHARMA
 
P/E (TTM) x 29.9 63.0 47.5% View Chart
P/BV x 2.9 10.1 29.0% View Chart
Dividend Yield % 0.9 1.3 73.7%  

Financials

 DR. REDDYS LAB   GSK PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
GSK PHARMA
Mar-17
DR. REDDYS LAB/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs3,3973,838 88.5%   
Low Rs2,5602,637 97.1%   
Sales per share (Unadj.) Rs856.5354.2 241.8%  
Earnings per share (Unadj.) Rs78.039.8 196.1%  
Cash flow per share (Unadj.) Rs139.942.9 326.3%  
Dividends per share (Unadj.) Rs20.0030.00 66.7%  
Dividend yield (eoy) %0.70.9 72.5%  
Book value per share (Unadj.) Rs739.8236.9 312.3%  
Shares outstanding (eoy) m165.7484.70 195.7%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x3.59.1 38.0%   
Avg P/E ratio x38.281.4 46.9%  
P/CF ratio (eoy) x21.375.5 28.2%  
Price / Book Value ratio x4.013.7 29.5%  
Dividend payout %25.775.4 34.0%   
Avg Mkt Cap Rs m493,632274,216 180.0%   
No. of employees `00022.74.7 482.9%   
Total wages/salary Rs m31,0684,830 643.2%   
Avg. sales/employee Rs Th6,259.06,387.0 98.0%   
Avg. wages/employee Rs Th1,369.81,028.3 133.2%   
Avg. net profit/employee Rs Th569.7717.1 79.4%   
INCOME DATA
Net Sales Rs m141,96130,000 473.2%  
Other income Rs m1,715728 235.5%   
Total revenues Rs m143,67630,728 467.6%   
Gross profit Rs m24,7224,190 590.1%  
Depreciation Rs m10,266263 3,903.4%   
Interest Rs m6340-   
Profit before tax Rs m15,5374,655 333.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m2,9651,744 170.0%   
Profit after tax Rs m12,9213,368 383.6%  
Gross profit margin %17.414.0 124.7%  
Effective tax rate %19.137.5 50.9%   
Net profit margin %9.111.2 81.1%  
BALANCE SHEET DATA
Current assets Rs m96,83716,742 578.4%   
Current liabilities Rs m84,1997,202 1,169.1%   
Net working cap to sales %8.931.8 28.0%  
Current ratio x1.22.3 49.5%  
Inventory Days Days7352 141.6%  
Debtors Days Days9821 470.0%  
Net fixed assets Rs m102,5528,635 1,187.6%   
Share capital Rs m829847 97.9%   
"Free" reserves Rs m121,79219,222 633.6%   
Net worth Rs m122,62120,069 611.0%   
Long term debt Rs m5,44910 54,490.0%   
Total assets Rs m218,16530,038 726.3%  
Interest coverage x25.5NM-  
Debt to equity ratio x00 8,918.0%  
Sales to assets ratio x0.71.0 65.2%   
Return on assets %6.211.2 55.4%  
Return on equity %10.516.8 62.8%  
Return on capital %12.925.5 50.7%  
Exports to sales %54.60-   
Imports to sales %9.40-   
Exports (fob) Rs m77,520NA-   
Imports (cif) Rs m13,274NA-   
Fx inflow Rs m81,670528 15,467.8%   
Fx outflow Rs m26,3557,193 366.4%   
Net fx Rs m55,315-6,665 -829.9%   
CASH FLOW
From Operations Rs m21,4442,360 908.6%  
From Investments Rs m-18,4043,008 -611.8%  
From Financial Activity Rs m-3,692-5,108 72.3%  
Net Cashflow Rs m-1,144260 -439.5%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 5.4 10.2 52.9%  
FIIs % 35.3 23.8 148.3%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 15.4 99.4%  
Shareholders   75,885 102,036 74.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   PIRAMAL ENTERPRISES  NOVARTIS  PANACEA BIOTECH  ORCHID PHARMA LTD  ABBOTT INDIA  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Feb 23, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS